
Sign up to save your podcasts
Or


Andre Bessette is the CEO of Eclipse Regenesis, a company developing a mechanical solution to short bowel syndrome. In this episode, Andre highlights the regulatory pathways available to solutions addressing needs in small patient populations. He also discusses clinical study site selection, payor engagement, and the current challenges of short bowel syndrome and necrotizing enterocolitis care.
By Impact1 at Stanford BiodesignAndre Bessette is the CEO of Eclipse Regenesis, a company developing a mechanical solution to short bowel syndrome. In this episode, Andre highlights the regulatory pathways available to solutions addressing needs in small patient populations. He also discusses clinical study site selection, payor engagement, and the current challenges of short bowel syndrome and necrotizing enterocolitis care.